Jim Cramer Didn’t Hold Back On SpaceX’s IPO & Discussed These 5 Stocks

1. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holdings in Q1 2026: 113

Johnson & Johnson (NYSE:JNJ)’s shares are up by 53% over the past year and by 15% year-to-date. Leerink Partners discussed the firm on May 13th as it upgraded the shares to Outperform from Market Perform and raised the share price target to $265 from $252. The financial firm commented that Johnson & Johnson (NYSE:JNJ)’s new drugs will inject momentum into the firm’s revenue growth and share price performance. Cramer has also discussed the firm’s drugs on several occasions over the past couple of months. For instance, in his Mad Money appearance on May 29th, the CNBC TV host compared Johnson & Johnson (NYSE:JNJ) to Merck and commented that “Merck’s cancer dominance has been challenged of late by JNJ.” In this tweet, he commented on the firm’s recent share price performance, which has seen Johnson & Johnson (NYSE:JNJ)’s shares gain 7.7% over the past month, in the context of illiquidity in the market:

“illiquidity =insane health care gains like Cardinal and JNJ”

Here is what Cramer said about Johnson & Johnson (NYSE:JNJ) on his April 24th appearance on Mad Money:

“Yeah, David, they’re hitting the pharma again, they’re killing healthcare. JNJ, one of the foremost companies of this country, 19 times earnings, down very badly. I don’t think it ends yet because this is a huge trade, out of healthcare, into semis and it’s really interesting because as you go out of a huge part of the market into a very concentrated area, tends not to act, tends not to be a good idea but people are doing it. I say look at the bargains in healthcare, some of the companies are going to come back and you’re going to regret that you sold them.”

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.